The Influence of Genetic Predisposition on Outcome After Catheter Ablation of Atrial Fibrillation. (AF GEN)
Untersuchung Des Einflusses Von Genetischem Risiko Auf Den Erfolg Einer Katheterablation Bei Paroxysmalem Und Persistierendem Vorhofflimmern
Study Overview
Detailed Description
Catheter ablation is an established standard therapy in interventional treatment of atrial fibrillation. electric isolation of the pulmonary veins, from which atrial fibrillation is originating in most patients, is cornerstone of all atrial fibrillation patients.
The most common cause for AF recurrence is still incomplete isolation of the pulmonary veins, on the other hand, only 80% of paroxysmal and 60 % of persistent patients can successfully be cured from atrial fibrillation (despite of isolated pulmonary veins after multiple ablation procedures).
By now, non-procedure related predictive risk factors, resulting in recurrence of atrial fibrillation after catheter ablation, are only partially identified, such as obesity, hypertension and sleep apnea.
In the past year several genetic risk alleles were identified, which are associated with atrial fibrillation. By now the relation between genetic risk, which is determined for every patient by its specific genotype and the outcome of catheter ablation in paroxysmal and persistent atrial fibrillation has not yet been investigated.
The aim is to investigate the influence of genetic risk for the recurrence of atrial fibrillation after catheter ablation.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Felix Bourier, MD
- Phone Number: 2020 +49891218
- Email: bourier@dhm.mhn.de
Study Contact Backup
- Name: Heike Starkmann
- Phone Number: 1192 +49891218
- Email: starkmannh@dhm.mhn.de
Study Locations
-
-
-
Munich, Germany, 80636
- Recruiting
- Deutsches Herzzentrum Muenchen
-
Contact:
- Isabel Deisenhofer, MD
- Phone Number: +49 89 1218 2020
- Email: deisenhofer@dhm.mhn.de
-
Sub-Investigator:
- Isabel Deisenhofer, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- patients planned for primary ablation due to paroxysmale or persistent atrial fibrillation
- written informed consent
Exclusion Criteria:
- patients under 18 years of age or patients not able to give informed consent
- prior left atrial ablation
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Influence of genetic risk on atrial fibrillation
Time Frame: 10ml blood sample taken at baseline visit (routine blood sample)
|
Analysation of the influence of genetic risk on the probability of recurrence of atrial fibrillation after catheter ablation
|
10ml blood sample taken at baseline visit (routine blood sample)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Bourier Felix, MD, Deutsches Herzzentrum München
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 304/20 S-KH
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.